公开(公告)号：US20120289684A1

公开(公告)日：2012-11-15

申请号：US13487828

申请日：2012-06-04

Applicant: Steven D. Levin ,  Mark W. Rixon ,  Zeren Gao

Inventor： Steven D. Levin ,  Mark W. Rixon ,  Zeren Gao

IPC: C07K16/00 ,  C07K16/42

CPC classification number: C07K14/7155 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32

Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Abstract translation: 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（IL-17RC / IL-17RA）部分的杂合可溶性受体。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。

公开(公告)号：US20110014656A1

公开(公告)日：2011-01-20

申请号：US12828041

申请日：2010-06-30

Applicant: STEVEN D. LEVIN ,  MARK W. RIXON ,  GAO ZEREN

Inventor： STEVEN D. LEVIN ,  MARK W. RIXON ,  GAO ZEREN

IPC: C12P21/02 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10

CPC classification number: C07K14/7155 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32

Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Abstract translation: 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）部分的杂合可溶性受体。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。

公开(公告)号：US07622116B2

公开(公告)日：2009-11-24

申请号：US11673094

申请日：2007-02-09

Applicant: Rolf E. Kuestner ,  Zeren Gao ,  Steven D. Levin ,  Mark W. Rixon

Inventor： Rolf E. Kuestner ,  Zeren Gao ,  Steven D. Levin ,  Mark W. Rixon

IPC: A61K39/395 ,  A61K38/00 ,  C07K14/00 ,  C07K17/00 ,  C12P21/08 ,  C07K16/00 ,  C07K17/14

CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K2121/00 ,  C07K14/715 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Abstract translation: 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 IL-17RC是IL-17A和IL-17F的常见受体。 本发明包括使用可溶性IL-17RC受体IL-17RCx4来治疗炎症的方法。

公开(公告)号：US20080241138A1

公开(公告)日：2008-10-02

申请号：US12055597

申请日：2008-03-26

Applicant: Steven D. Levin ,  Mark W. Rixon ,  Gao Zeren

Inventor： Steven D. Levin ,  Mark W. Rixon ,  Gao Zeren

IPC: A61K39/00 ,  C07K16/00 ,  C07K14/00 ,  C07H21/04 ,  C12N15/00 ,  C12Q1/00 ,  C12N5/00 ,  C12P21/04 ,  A61K38/00

CPC classification number: C07K14/7155 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32

Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Abstract translation: 公开了IL-17A和IL-17F的拮抗剂。 拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）部分的杂合可溶性受体。 这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。 还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。

公开(公告)号：US4871175A

公开(公告)日：1989-10-03

申请号：US220961

申请日：1988-07-14

Applicant: Steven D. Levin ,  William A. Swenson

Inventor： Steven D. Levin ,  William A. Swenson

IPC: A63B69/36

CPC classification number: A63B69/3667 ,  Y10S273/01

Abstract: A portable and foldable two-piece alignment training device for golfers includes two sets of elongated strips, each set having three strips hingeably joined at their first ends. The two strip sets are joined together by an adjustable slide clip and placed on the ground to form an "I". The "I" pattern keys the golfer to align his swing thereto. Indicia indicate tee position, the golfer's body and foot position, flight direction of the ball, and retraction distance of the club from the tee.

Abstract translation: 用于高尔夫球手的便携式和可折叠两件式对准训练装置包括两组细长条，每组具有在其第一端可铰接地连接的三个条。 两个带组通过可调节的滑动夹连接在一起并放置在地面上以形成“I”。 “I”图案使高尔夫球手将其摆动对准。 标记表示三通位置，高尔夫球员的身体和脚位置，球的飞行方向以及球杆从三通的回缩距离。